Huawei is advancing its contributions to cardiovascular health research with studies involving wearable devices gaining recognition at international medical conferences.
Research involving Huawei wearables was cited in the 2026 Asia Pacific Atrial Fibrillation Guidelines during the APHRS 2026 event in South Korea. The study explored links between sleep apnea, arrhythmia, blood pressure, and cardiovascular events using device data.
Meanwhile, Huawei showcased blood pressure monitoring innovations at the ISH-ECS 2026 meeting in Dubai. The company also highlighted its collaboration with the International Society of Hypertension through a dedicated innovation fund.
Advancing Blood Pressure Research
Huawei introduced a minimally disruptive ambulatory blood pressure monitoring initiative at the conference. Developed with Ruijin Hospital, this hybrid approach combines continuous photoplethysmography monitoring with airbag-based readings to reduce reliance on traditional cuffs.
Professor Wang Jiguang noted that these innovations help shape a new direction for automated blood pressure management. Wearable devices seamlessly embed these health checks into daily life for users.
Health Tracking Features
The Huawei Watch GT 7 Pro and Watch D3 feature a one-tap Health Glance assessment. This tool analyzes heart rate, heart rate variability, blood oxygen levels, arterial elasticity, and ECG data in seconds.
These metrics generate a comprehensive report to help users spot potential health risks early. Huawei remains committed to using smart technology to make advanced heart and blood pressure care accessible.
To learn more about these devices, visit Huawei’s official Facebook and Instagram pages.
